Immunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of “Moderate Buy” by Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $65.64.

Several equities analysts have issued reports on IMCR shares. Needham & Company LLC reissued a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th.

Insider Buying and Selling at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. purchased a new position in Immunocore during the fourth quarter worth approximately $4,868,000. GF Fund Management CO. LTD. purchased a new stake in shares of Immunocore during the 4th quarter valued at about $25,000. Woodline Partners LP lifted its position in shares of Immunocore by 19.4% during the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock worth $9,678,000 after purchasing an additional 53,378 shares in the last quarter. Tang Capital Management LLC grew its stake in shares of Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock valued at $45,890,000 after acquiring an additional 450,000 shares in the last quarter. Finally, Tema Etfs LLC bought a new stake in shares of Immunocore in the fourth quarter worth $330,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Down 1.1 %

Immunocore stock opened at $29.32 on Friday. The stock has a 50 day moving average of $30.00 and a two-hundred day moving average of $31.02. Immunocore has a twelve month low of $27.19 and a twelve month high of $66.00. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -30.86 and a beta of 0.79. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.